Atlas Trials

A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer

Clinical trial NCT02613208 · COMPLETED

Trial details

NCT number
NCT02613208
Sponsor
Hoffmann-La Roche
Status
COMPLETED
Study type
OBSERVATIONAL
Breast Cancer
Start date
2015-12-09
Primary completion
2018-12-03
Enrollment
111

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.